44 results
424B3
INM
InMed Pharmaceuticals Inc.
27 Jun 24
Prospectus supplement
6:27pm
, and in the event of any resultant adverse publicity, our reputation may be harmed. Furthermore, if our Product Candidates are classified as “controlled substances … and requirements, which could subject us to significant liability and harm our reputation.
We are exposed to the risk of employee fraud or other misconduct
8-K
EX-10.1
INM
InMed Pharmaceuticals Inc.
9 Feb 24
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
12:34pm
in lieu of notice of termination, damages for loss of reputation, loss of position, loss of status, loss of future job opportunities, and constructive
8-K
EX-10.1
rvs9u4dafw7g8em
19 Jul 22
InMed Announces Appointment of Chief Operating Officer
7:43pm
424B3
ycganxf
6 Jul 22
Prospectus supplement
2:43pm
424B5
cl9rhpisd0qv7xctc jc
3 Jun 22
Prospectus supplement for primary offering
9:45pm
424B3
felieyh6nx8
25 Apr 22
Prospectus supplement
5:02pm
424B3
m1oz 2mdqq
7 Apr 22
Prospectus supplement
4:46pm
S-3
aej25dvsc5ahcq5y
4 Feb 22
Shelf registration
4:36pm